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Methodological differences among cross-cultural studies of vasomotor symptoms 2 
limit attempts at comparison or systematic review. We reviewed only cross-cultural 3 
studies of menopausal symptoms that explicitly examined symptoms in general 4 
populations of women in different countries or different ethnic groups in the same 5 
country. This resulted in the inclusion of nine studies: Australian/Japanese Midlife 6 
Women’s Health Study (AJMWHS), Decisions At Menopause Study (DAMeS), Four 7 
Major Ethnic Groups (FMEG), Hilo Women's Health Survey (HWHS), Mid-Aged 8 
Health in Women from the Indian Subcontinent (MAHWIS), Penn Ovarian Aging 9 
Study (POAS), Study of Women's Health Across the Nation (SWAN),Women’s Health 10 
in Midlife National Study (WHiMNS), and Women’s International Study of Health and 11 
Sexuality (WISHeS). 12 
Vasomotor symptoms generally include hot flushes and night sweats although 13 
other associated symptoms exist. Prevalence rates vary between and within 14 
populations, and data on frequency and bothersomeness/severity should be collected. 15 
Significant cultural differences in vasomotor symptoms were observed in 8/9 studies, 16 
and symptoms were influenced by the following determinants: menopausal status, 17 
hormones (and variance), age (or actually, the square of age, age
2
), education, BMI, 18 
depression, anxiety, poor physical health, perceived stress, lifestyle factors (hormone 19 
therapy use, smoking and exposure to passive smoke), and acculturation (in 20 
immigrant populations). These studies highlight the methodological challenges 21 
involved in conducting multi-population studies, particularly when languages differ, 22 
but also highlight the importance of performing multivariate and factor analyses. 23 
Recommendations are made to improve methodological rigor and facilitate 24 
comparisons in future cross-cultural menopause studies. 25 
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1. Introduction 1 
Vasomotor symptoms (VMS) are considered hallmark symptoms of menopause in 2 
most cultures. Cross-cultural differences in the prevalence and experience of VMS 3 
have been well-documented [1-3], but rigorous comparisons are hampered by 4 
methodological differences [2]. In order to increase the understanding of cultural 5 
variation in, and influences on, VMS and to improve methodological rigor in future 6 
research, this review examines nine studies that explicitly compare symptoms across 7 
different cultural (country/ethnic) groups using similar methodology: Australian/ 8 
Japanese Midlife Women’s Health Study (AJMWHS) [4], Decisions At Menopause 9 
Study (DAMeS [5-9]), Hilo Women's Health Survey (HWHS) [10-12], Four Major 10 
Ethnic Groups (FMEG) [13]; Mid-Aged Health in Women from the Indian 11 
Subcontinent (MAHWIS)[14, 15]), Penn Ovarian Aging Study (POAS) [16-19], Study 12 
of Women's Health Across the Nation (SWAN) [20-28], Women’s Health in Midlife 13 
National Study (WHiMNS) [29]; and Women’s International Study of Health and 14 
Sexuality (WISHeS) [30]. The objectives of this review are to: (1) assess whether 15 
VMS differ cross-culturally; (2) identify determinants of VMS; (3) make 16 
recommendations on methods for future cross-cultural studies. 17 
2. Methods 18 
This review includes only studies that compare VMS frequencies across 19 
ethnic groups within or between countries. The studies are described in detail in the 20 
overview to this series of review papers [31].  21 
 We reviewed methodological and study design characteristics, frequencies of 22 
VMS, and determinants of VMS identified in multivariate analyses in the studies. 23 




Recommendations are made throughout this review to enable more rigorous 1 
cross-cultural comparisons in future research. 2 
3. Results and Discussion 3 
3.1 Study design and methodological considerations 4 
3.1.1 Study design 5 
 Following an earlier publication [2], this review focuses on publications since 6 
2004. Individual studies utilized similar instruments and methodology for comparison 7 
between subpopulations, but design characteristics and methods varied considerably 8 
among studies (Table 1 and Overview [31]). Eight of 9 studies documented 9 
significant cultural (ethnic/country) differences in VMS (Table 2), but more rigorous 10 
comparisons across studies would be facilitated by greater standardization of 11 
methodology and study design. 12 
 Detailed discussion of and recommendations concerning methodological issues 13 
can be found in the Overview [31]. We must distinguish between occurrence, 14 
perception and reporting of VMS [20], as these are differently assessed by different 15 
methods and mediated by language. Most studies translated and administered 16 
language-specific versions of questionnaires, but some (FMEG, HWHS) did not. 17 
Linguistic variation in symptom terminology complicates estimates of symptom 18 
prevalence and highlights potentially more nuanced physiological experiences. Rates 19 
of hot flush prevalence in one Japanese population differed by more than 7-fold, 20 
depending on the term [32]. To avoid influence of menopausal stereotypes on 21 
reporting, VMS should be embedded in an everyday complaint list, as in DAMeS and 22 
HWHS. 23 
 To characterize relevant variation in the menopausal transition, we recommend 24 
an age range of 45-55. This could be expanded to 40-60 if a more extended profile is 25 




desired, or shifted earlier in populations with earlier age at menopause or in 1 
longitudinal studies (when inclusion of more premenopausal women at baseline 2 
would be recommended). However data should be reported for ages 45-55 to enable 3 
cross-study comparisons. Most questionnaires use either a 2-week or 1-month recall 4 
period. A shorter recall period may be more accurate, but a 1-month recall period 5 
covers an average menstrual cycle. We need studies that ask both, to provide data on 6 
how these are related (e.g., are 1 month recall rates similar to or double 2-week recall 7 
rates?) and to assess how they may change by factors such as menopausal status. 8 
Longer or ambiguous recall periods should not be used, although it may be 9 
informative to ask women if they have ever experienced VMS. 10 
  11 
3.1.2 Constituent vasomotor symptoms 12 
 Hot flushes (HFs) are the defining VMS, but associated symptoms vary 13 
considerably between studies, and include thermoregulatory, sexual and sleep-related 14 
symptoms. Many studies include night sweats (NSs), which are HFs that occur at 15 
night with significant perspiration. These may disturb sleep, and sleep troubles may 16 
be a proxy for them in symptom reports. The extent to which sleep and sexual 17 
symptoms (see Sexual review [33]) are associated with vasomotor symptoms is 18 
influenced by cultural and individual practices related to sleep [34] and sexual 19 
behavior. In DAMeS, sleep disturbances were associated with VMS in Spain but with 20 
general somatic symptoms in Morocco [9]. HFs and NSs have been shown to have 21 
different determinants [35], and thus should be queried separately to enable 22 
comparisons between studies.  23 
 WISHes examined age patterns of symptom prevalence in women aged 20-70yrs 24 
and found that in addition to HFs and NSs, vaginal dryness, sexual arousal difficulties, 25 




sleeping difficulties, aches from head to shoulders, and poor memory also peaked at 1 
age 50, the average age of menopause [30]. In contrast, symptoms such as sweating, 2 
sexual desire changes, and psychological symptoms peaked earlier [30]. Thus 3 
difficulty sleeping, vaginal dryness and sexual arousal difficulties might share 4 
underlying etiology with VMS. 5 
 6 
3.1.3 Factor analyses 7 
 Factor analysis identifies symptoms that can be classified together (often assumed 8 
to share underlying etiology, such as hormonal changes), based on statistical rather 9 
than a priori concepts, to which cross-cultural work is particularly susceptible. Factor 10 
analysis can determine whether VMS constitutes a unique symptom factor and 11 
whether other symptoms are associated with VMS.  12 
 In DAMeS, factor analysis of the 20 symptoms shared among sites resulted in up 13 
to 8 factors in different countries. When final factor analyses were constrained to 14 
permit only three factors, HFs factored with sexual symptoms in Spain and with 15 
somatic symptoms in Morocco, but were not included in the US or Lebanon final 16 
solutions [9]. When more factors were permitted, HFs often showed high factor 17 
loading scores, suggesting that for some populations a greater number of factors may 18 
be required to include this symptom (rated most bothersome in 3 of 4 sites), 19 
particularly when everyday complaint lists are used [36]. In WHiMNS, HFs were 20 
excluded a priori [29], and thus assumed to constitute a unique symptom factor.  21 
 In DAMeS, HFs and NSs did not load onto the same factor as anxiety and 22 
depression in any country. Similarly in SWAN, two consistent symptom factors 23 
emerged from analyses across ethnic groups: vasomotor and 24 
psychological/psychosomatic [22]. In HWHS, factor analyses identified 3 factors, 25 




with one factor containing HFs, NSs, loss of sexual desire, trouble sleeping and 1 
vaginal dryness [11]. Cross-sectional results may differ from longitudinal studies, as 2 
POAS found that psychological factors were associated with, and even predicted, 3 
VMS [18]. 4 
 We recommend that factor analyses should be performed on the whole sample as 5 
well as each subgroup separately as in DAMeS; and all symptoms with high 6 
prevalence should be included in final solutions (the number of factors should not be 7 
limited a priori, so that symptoms associated with HFs can be assessed). 8 
 9 
3.1.4 VMS Measures 10 
4.1.4.1. Subjective 11 
Self-reported symptoms often include measures of frequency, severity, and/or 12 
bothersomeness. Of these, frequencies may be the most comparable across cultures 13 
because populations may vary in the degree to which they are bothered by symptoms 14 
or rate their severity. HF frequencies range from 21 to 84%, but methodological 15 
differences between studies render comparisons difficult (Table 3).  16 
Although HF frequency generally accounts for the majority (60-75%) of 17 
variability in treatment outcome, additional information is gained from severity [37]. 18 
If a single endpoint is desired, a combined Frequency x Severity score could be used 19 
[36, 37]. The terms severity and bothersomeness are often used interchangeably. 20 
While severe symptoms are likely to be bothersome, this may not always be the case. 21 
For example, severe HFs at home or in cold environments may be less bothersome 22 
than less severe HFs in public (where removing clothes is not possible) or in warmer 23 
environments.  24 




Not all women who experience VMS are bothered [24], but bothersomeness may 1 
be important to quality of life (QOL). In DAMeS, there appeared to be a correlation 2 
between frequency and bothersomeness of HFs, as well as other emotional and 3 
somatic symptoms [7]. In SWAN, negative affect, symptom sensitivity, sleep 4 
problems and number of visits reporting HFs were associated with HF bother, even 5 
after adjusting for HF frequency [24]. Women with frequent but not bothersome HFs 6 
had lower negative affect and were more likely to be married. Women with infrequent 7 
but bothersome HFs were more likely to be in poorer health, have lower education, 8 
and to be African-American vs. Caucasian, and less likely to be Japanese [24]. Since 9 
perception of severity or bothersomeness may exhibit significant cultural differences, 10 
collection of such data in addition to frequency is recommended. 11 
 12 
3.1.4.2. Objective 13 
While most studies of menopausal symptoms rely on subjective report, recent 14 
studies have used skin conductance as an ‘objective’ measure of thermoregulatory 15 
instability associated with HFs [10, 38]. However, skin conductance relies on 16 
sweating, and HFs are heat dissipation events that involve vasodilation but not always 17 
sweating. Thus measurements do not exhibit one-to-one correspondence with 18 
self-reports [39], suggesting that information on severity or bothersomeness may be 19 
important, particularly in terms of QOL. Ambulatory HF monitors have been 20 
developed [40, 41], and are recommended for use in future cross-cultural studies. 21 
 In a 24-hour ambulatory study and a 3-hour laboratory study in HWHS, 22 
Japanese-Americans (JAs) and European-Americans (EAs) showed no significant 23 
differences between reported or objectively demonstrated HFs. In contrast, 2-week 24 
recall of bothersome symptoms was significantly lower in JAs, possibly due to 25 




reporting bias because JAs also reported fewer symptoms of other conditions [10]. 1 
Lower recall of bothersome HFs by JAs [12] might also result from physiological 2 
differences in HFs, as JAs experienced fewer HFs as flushing with an associated 3 
change in pulse compared to EAs [10]. 4 
 Subjective and objective measures of HFs may provide insight into the range of 5 
differences between occurrence, perception and bothersomeness [20]. Thus, future 6 
research should collect data on symptom frequency (subjective and objective) and 7 
severity and/or bothersomeness (as measure of interference with daily life activities 8 
and QOL).  9 
 10 
3.2 Determinants of vasomotor symptoms 11 
 To answer the question of whether cultural differences in VMS derive from 12 
confounding variables that exhibit cultural variation, and to identify determinants of 13 
menopausal symptoms (Table 4), multivariate analyses are essential. Many factors 14 
appear significant in bivariate analyses, but are no longer significant in multivariate 15 
models. 16 
 WISHeS reported regression coefficients, permitting estimation of symptom 17 
prevalence at age 50 in subpopulations with various determinants [30]. For example, 18 
the estimated prevalence of HFs = 36.8 + 3.9*(# mental morbidity items) + 2.1*(# 19 
physical morbidity items) + 5.8*(early surgical menopause: yes=1, no=0). Thus for 20 
50-year old women with no morbidity and not surgically menopausal, 36.8% would 21 
be expected to have HFs. For 50-year old women with early surgical menopause, 2 22 
chronic physical diseases, and 3 mental morbidity items, the prevalence of HFs would 23 
be 56.7%. Similar regression analyses in non-western populations with additional 24 




determinants may lead to more complex and culturally-diverse models of VMS 1 
variability and midlife symptoms in general. 2 
 3 
3.2.1. Culture (country/ethnicity) 4 
 The 9 studies reviewed here used country (3/9), ethnicity (5/9) and both (1/9) as 5 
proxies for cultural group, and ranged from only western countries with similar health 6 
profiles (mean BMI ≥ 25, clinically overweight) (WISHeS) to more culturally diverse 7 
populations such as Western/Asian (AJWMHS, MAHWIS) and US/European/Middle 8 
Eastern (DAMeS). Seven of the eight studies conducting multivariate analyses on 9 
VMS reported significant differences in VMS by culture group (only WISHeS, with 10 
significance P<0.001, did not). Yet the significance of difference decreased in some 11 
studies when confounding variables were controlled for (POAS) but not in others 12 
(SWAN, WHiMNS). 13 
 14 
3.2.2. Menopausal status and hormonal  15 
 After adjusting for other risk factors, menopausal status showed the most 16 
consistent association with HFs. Data on menopausal status should be collected and 17 
reported following STRAW stages [42, 43], and data on surgical menopause and 18 
hormone therapy (HT) use should be collected and reported separately. Comparison 19 
of VMS frequency is complicated by varying rates of HT use, ranging from 0% 20 
among surgically menopausal women in Morocco to 42% among postmenopausal 21 
women in the US (DAMES) [7].  22 
 Hormone data may clarify menopausal status, and be correlated with VMS. In the 23 
POAS, the standard deviation in estradiol (E2), but not E2 levels were significantly 24 
associated with symptoms, highlighting the importance of repeated measures and 25 




measures of variability over the menopausal transition [18]. In the SWAN, serum sex 1 
steroid, FSH and SHBG levels varied by ethnicity, but were highly confounded by 2 
ethnic disparities in body size [25].  3 
 4 
3.2.3. Demographic  5 
  Truly menopausal symptoms, the increased prevalence of which is due to 6 
underlying changes of menopause, should exhibit an inverted U-shaped curve with 7 
age (or an inverse relationship with age
2
), achieving maximum prevalence around the 8 
average age of menopause (50 yrs), while symptoms of aging should exhibit a 9 
positive linear relationship with age. In WISHeS, all of the symptoms that peaked at 10 
50 had significant regression coefficients for early reproductive surgery, no 11 
significant coefficients for age, negative coefficients for age
2
 (ie, inverted parabola), 12 
and significant positive coefficients for mental and physical morbidity [30] Thus 13 
controlling for age or menopausal status in a linear fashion is inadequate, and future 14 
studies of midlife symptoms should include a quadratic age term in models. 15 
 When examined, demographic factors such as socioeconomic status and 16 
education showed inconclusive or non-significant patterning across studies. Education 17 
showed a negative relationship with VMS in 2 studies, a positive relationship in one 18 
study, and was not significant in two studies.  19 
 20 
3.2.4. Anthropometric 21 
 High BMI may increase the risk of HFs due to increased insulating effects of 22 
excess body fat [26, 27], which may increase core body temperature. BMI exhibited 23 
positive relationships with VMS in 2/5 studies, and a strong positive relationship with 24 
total symptom number in FMEG.  25 





3.2.5. Mental/physical health 2 
Measures of mental and physical morbidity should be included in any 3 
cross-cultural study of menopausal symptoms, as these often vary by culture group 4 
and contribute significantly to prevalence (and bothersome) rates (see Psychological 5 
symptom review [44] and Somatic symptom review [45]). Both depression and 6 
anxiety were positively related to VMS in 3/3 studies. Women with depression were 7 
more likely to report HFs (POAS and WHiMNS), and an Australian longitudinal 8 
study showed that depression often preceded HFs [46]. In POAS, anxiety scores at 9 
previous assessment significantly predicted HFs, with those reporting high anxiety 10 
being nearly 5 times more likely to experience HFs [19]. Physical morbidity and 11 
perceived stress were positively related to VMS in 3/4 and 2/2 studies, respectively.  12 
 13 
32.6. Lifestyle 14 
Lifestyle variables included in the studies reviewed here are not exhaustive, and 15 
lack of significant relationships may reflect inadequate variation or statistical power. 16 
However, smoking and passive smoke exposure were identified as significant 17 
determinants of VMS. Dietary factors such as soy isoflavones were not [21], possibly 18 
due to relatively low intake levels compared to Asian intakes [2, 47]. Religion was not 19 
significant in studies reviewed here, but religious differences have been observed in 20 
other studies [38]. Hormone therapy is included in Table 4 as a lifestyle variable 21 
because, although HT use influences endogenous hormone concentrations, it also 22 
reflects access to medical care and medicalization of menopause. 23 
 Attitudes toward menopause and medicalization of menopause vary 24 
cross-culturally [3], and may influence rates of VMS reporting. Westernization, 25 




acculturation and medicalization are not always highly correlated and future research 1 
is required to parse the variance in VMS attributed to these factors. In DAMeS, the 2 
highest HF rates were reported in the site (Morocco) that is least medicalized, and 3 
where the traditional vocabulary does not even have a word for menopause [7]. In the 4 
SWAN, Chinese- and Japanese-American women who were least acculturated tended 5 
to report more negative attitudes toward the menopause [28], yet had lower rates of 6 
vasomotor symptoms compared to African-, Caucasian- and Hispanic-Americans. In 7 
contrast, in MAHWIS, UK Asian women who were less acculturated reported more 8 
VMS [14]. In MAHWIS, although UK Asian and Delhi women reported poorer health 9 
and higher physical and emotional symptoms than the UK Caucasian, the 2 UK 10 
groups reported significantly higher rates of HFs and night sweats than the Delhi 11 
group [15], suggesting that westernization might correlate with higher rates of VMS.  12 
 13 
3.2.7. Environmental variables 14 
Ethnic and cultural differences in VMS frequency may derive not only from 15 
individual physiological and lifestyle differences but also environmental differences 16 
such as ambient temperature [48, 49], which may be influenced by indoor heating and 17 
air conditioning. 18 
 19 
4. Conclusions 20 
Among menopausal symptoms, VMS are of great clinical importance, as they 21 
impact quality of life and often lead women to seek treatment. Evaluation of how 22 
VMS rates vary between cultural (country and ethnic) groups, and which factors 23 
influence them, has been complicated by methodological and reporting differences. 24 
Culture group was not significant in regression analyses of HFs in WISHeS, nor in 25 




AJMWHS. In POAS ethnic differences decreased significantly when many 1 
confounding variables were controlled for in adjusted models [16], suggesting that in 2 
same country multi-ethnic studies much of the variability may be attributed to 3 
confounding variables that correlate with ethnicity. In contrast, SWAN found 4 
significant ethnic differences even after adjusting for many covariates [21]. In studies 5 
such as DAMeS and MAHWIS with greater cultural differences between populations 6 
(e.g., western, Middle Eastern, Asian), country differences remained significant, even 7 
in multivariate models, suggesting that indeed there may be true cultural differences, 8 
or at least that the relevant local biological factors have not yet been identified [50]. 9 
 Cross-cultural differences in VMS are likely confounded by differences in 10 
important determinants such as hormonal, health, and lifestyle factors. Of the 11 
determinants examined by at least 3 studies (ie, denominator of 3 or greater in 12 
Summary column of Table 4), age, menopausal status and mental/physical health 13 
factors were significant in a majority of the studies. Few studies found significant 14 
relationships with the following: demographic variables such as education and 15 
employment status; lifestyle variables such as smoking, activity level and diet; and 16 
BMI. However, inadequate variation in variables such as BMI and activity level, and 17 
lack of statistical power, might explain these results. Additionally, in some studies the 18 
most appropriate variable may not have been examined: exposure to passive smoke 19 
might be more important than smoking (as in SWAN), and age
2
 might be better than 20 
age (WISHeS). 21 
 Recommendations on study design and analysis are presented in Table 5. With 22 
the exception of hormonal data and objective measures of hot flushes, all of these 23 
recommendations can be easily followed in any study, thereby strengthening the field 24 
of menopausal research and facilitating cross-cultural comparisons. In choosing which 25 




data to collect, researchers must evaluate issues and constraints such as: subject and 1 
researcher burden; invasiveness (eg, daily diaries may be more burdensome for some 2 
than wearing a HF monitor or having blood drawn); cost; questionnaire administration 3 
(ranging from postal questionnaires not requiring interviewer contact to those 4 
requiring blood samples, dietary assessments and objective HF measurements). For 5 
variables such as socioeconomic status and activity level, relative assessments (e.g., 6 
financial comfort, or ability to meet basic needs in local context) may be more useful 7 
than absolute numbers.  8 
 Non-vasomotor symptoms, such as psychological symptoms (eg, anxiety and 9 
depression), may influence VMS or be influenced by them (eg, night sweats may 10 
affect sleep). Thus even if the primary interest is VMS, collection of data on other 11 
symptoms is important. Future research should build on the foundational studies 12 
reviewed here and methodological recommendations proposed in this review and the 13 
Overview [31] , to identify local cultural and biological determinants that will explain 14 
more of the observed cross-cultural variability in vasomotor symptoms and 15 
experience. 16 
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